Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

Comparison of mutational landscape in primary and metastatic pancreatic tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...

在非小细胞肺癌中，KRAS基因突变的比例不是特别高，其中KRAS基因G12C突变在白种人突变的概率是10%，在亚裔患者的突变概率是3%。经过数十年的研究，针对KRAS基因G12C目前已经有了靶向药，Sotorasib（中文翻译为：索托拉西布）是一种口 ...

Deep learning–powered analysis of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

2025 Potential U.S. commercial launch in recurrent KRAS mutant LGSOC planned for mid-2025 RAMP 205 trial in 1L metastatic ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.

Silexion Therapeutics shares preclinical data on SIL-204, highlighting tumor reduction in KRAS-driven cancers and sustained drug efficacy for 56+ days.